Eduardo Tormo
Madrid, MD 28019, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer.
Journal: Molecular medicine (Cambridge, Mass.)
Published: January 13, 2025
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.
Journal: Cell death discovery
Published: April 09, 2024
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
Journal: International journal of molecular sciences
Published: December 12, 2022
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Journal: Science advances
Published: May 20, 2022
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Journal: Cancer metastasis reviews
Published: August 14, 2021
miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker.
Journal: Breast cancer : basic and clinical research
Published: June 02, 2020
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.
Journal: Cancers
Published: November 05, 2019
The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.
Journal: International journal of molecular sciences
Published: May 20, 2016
Last Updated: 09/26/2026